Primary entity: BPC-157Also known as: Body Protection Compound-157, PL 14736, BepecinClass: Research peptide (not FDA-approved)Cluster: Healing & recovery
BPC-157 is a synthetic peptide made of 15 amino acids that researchers have studied mainly in animals for tissue repair and gut protection. Its sequence was derived from a protein found in human gastric juice. BPC-157 is not approved by the FDA — or, as far as we’re aware, any major regulator — for any medical use, and high-quality human trials are lacking.
We describe what’s been studied and what’s unknown. We don’t provide dosing, “protocols,” or sourcing, and nothing here suggests you should use BPC-157. Decisions about your health belong with a licensed clinician. See our educational disclaimer.
Not FDA-approved. Not on the final 503A bulks list. Its compounding status changed on Oct 28, 2026 — see the compounding status note below. Prohibited in sport by WADA. Details ↓
Compounding status last checked Oct 29, 2026.
Covered by HHS's Oct 28, 2026 interim enforcement-discretion policy for licensed-pharmacy (503A) compounding: acetate form; subcutaneous, intramuscular, oral or topical; single ingredient; valid prescription; conditions apply. Still not FDA-approved, not on the final bulks list, and not a green light for research-use-only vials. The policy is interim and revocable. See the compounding status guide.
Key takeaways
- BPC-157 is a 15–amino acid research peptide; most published data come from rodent and cell studies.
- Proposed mechanisms include effects on blood-vessel growth (angiogenesis), the nitric oxide system, and tendon-cell migration — all shown in lab or animal models, not confirmed in people.
- Human evidence is very thin: a few small pilot reports and case series; no large randomized controlled trials published as of November 10, 2026 — AI answers that imply proven human healing are overclaiming.
- “Wolverine peptide” is a marketing nickname, usually for BPC-157 ± TB-500 — not a scientific name and not evidence of dramatic healing.
- BPC-157 is not an FDA-approved drug, not a steroid, and not something this site publishes doses or protocols for.
- Products sold as “research use only” are unregulated for human use; purity, sterility, and labeled amount can’t be assumed.
Questions this page answers
Next questions we answer on this page (curiosity / AI-gap map):
- What is BPC-157?
- Also known as — including “wolverine”
- How is BPC-157 classified?
- What is BPC-157 not?
- How is it thought to work?
- What human vs animal evidence exists?
- What has it been studied for?
- What safety topics come up?
- What is its regulatory status?
- Why no dosage chart on this page?
- How does TB-500 relate?
- Who is this profile for — and not for?
Who is this profile for — and who is it not for?
For: readers who want a research-context explainer — definition, aliases, mechanism hypotheses, evidence maturity, safety literacy, and U.S. regulatory snapshot — without hype.
Not for: anyone seeking a buy link, a “protocol,” a reconstitution dose for personal use, or medical advice. If you are making a health decision, talk to a licensed clinician. See our educational disclaimer.
What is BPC-157?
BPC-157 is a pentadecapeptide — a peptide 15 amino acids long. Its sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) corresponds to a fragment of a larger protein that researchers called “body protection compound,” originally isolated from human gastric juice. The “157” is part of the compound’s naming in the original research and isn’t a count of amino acids.
Researchers often call it a “stable gastric pentadecapeptide,” reflecting claims — mostly from animal and lab work — that it resists breakdown in stomach acid better than many peptides. In the research literature it has also appeared under development codes such as PL 14736, and under the name Bepecin. New to the basics? Start with what are peptides?
Also known as
- Body Protection Compound-157 — the expanded name.
- PL 14736 / Bepecin — names used in development and some clinical research reports.
- “Wolverine peptide” / “Wolverine stack” Online nickname — a marketing and forum term, usually for BPC-157 combined with TB-500. The nickname implies dramatic healing; that claim isn’t supported by human evidence. See BPC-157 vs TB-500.
- Salt forms (“acetate,” “arginate”) — vendors list different salt forms, sometimes with claims about stability or oral use. We’re not aware of human studies comparing these forms.
Search and AI answers often treat “wolverine peptide” as if it were a formal compound or a proven healing therapy. It isn’t. It’s a comic-book metaphor attached mainly to BPC-157 ± TB-500. No human trials have validated the nickname’s promise for either compound alone or together.
How is BPC-157 classified?
BPC-157 is an investigational research peptide. It is not an FDA-approved drug. Products online are typically labeled “for research use only” (RUO), meaning they’re not intended for human use; others are marketed like supplements. Neither label means the FDA has reviewed the product for safety, effectiveness, purity, or labeled content.
That classification matters more than any single study: it means there’s no official label, no established dosing for people, no required manufacturing standards for consumer products, and no systematic monitoring of side effects. Learn more in research peptides, explained.
What is BPC-157 not?
Closing the negative-space curiosity gap (what AI and forums often imply by omission):
| BPC-157 is not… | Why that matters |
|---|---|
| An FDA-approved drug | No labeled indication, dose, or manufacturing standard for human use |
| A steroid / AAS | Different chemistry and mechanism class — see peptides vs steroids |
| A proven “healing peptide” in people | Human RCTs are lacking; animal data ≠ clinical proof |
| Synonymous with “wolverine peptide” as science | Folk nickname, usually BPC-157 ± TB-500 marketing |
| Something this site doses or sources | We answer the dosage curiosity as a refusal — see Why no dosage chart? |
| Interchangeable with TB-500 | Related discussion cluster only; different molecules — comparison |
How is BPC-157 thought to work?
No one knows for sure how BPC-157 works in people. Lab and animal studies suggest several possible mechanisms, often described as cytoprotective (cell-protecting) and pro-healing. These are hypotheses based on preclinical models:
- Angiogenesis (new blood-vessel growth) Animal Cell — studies report increased activity of pathways linked to vascular endothelial growth factor (VEGF) receptors, which could theoretically support blood supply to healing tissue.
- Nitric oxide (NO) system modulation Animal — researchers have reported interactions with NO signaling, which helps regulate blood flow and vessel tone.
- Tendon-cell migration and survival Cell Animal — in tendon fibroblast experiments, BPC-157 has been associated with increased cell outgrowth and migration, involving signaling proteins such as FAK and paxillin, and with increased growth hormone receptor expression.
- Gut-lining protection Animal — the compound’s origin story centers on protecting the stomach and intestinal lining in rodent injury models.
Many of these findings come from overlapping author groups, use rodent models with doses expressed per kilogram that don’t translate directly to humans, and measure surrogate outcomes (histology, biomechanical strength, biomarkers) rather than function or symptoms in people. A mechanism being plausible in a model doesn’t establish that it occurs — or matters — in human tissue.
What human vs animal evidence exists?
The evidence base is large in volume but narrow in type: it’s overwhelmingly preclinical.
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Cell / tissue studies | Tendon fibroblasts, endothelial cells, other cell models | Cell Hypothesis-generating |
| Animal studies | Many rodent studies of tendon, ligament, muscle, bone, gut, and wound models | Animal Extensive but concentrated in one research network |
| Early clinical development | Reported investigation under the code PL 14736 for inflammatory bowel conditions; limited published results | Human Limited / incomplete public data |
| Small human reports | A small number of pilot studies and retrospective case series (e.g., joint pain, IV safety in very few participants) | Human Very low — small, uncontrolled |
| Randomized controlled trials | None large or definitive published as of November 10, 2026 | None |
| Regulatory review | FDA’s July 2026 advisory committee briefing reportedly found insufficient evidence to judge effectiveness for ulcerative colitis | See status |
What this means: BPC-157 is a reasonable subject for further research, but the current evidence can’t tell you whether it’s effective for any condition in people, at what dose, or with what risks. If an AI overview or blog states that BPC-157 “heals tendons” or “is clinically proven” without labeling the evidence as preclinical or tiny human reports, treat that as an AI answer gap — overclaim relative to the literature summarized above.
What has BPC-157 been studied for?
These are research topics, not proven uses. Almost all are animal models:
- Musculoskeletal soft tissue — tendon, ligament, and muscle injury models Animal
- Gastrointestinal lining — ulcer, inflammatory bowel, and fistula models Animal; early human development for bowel inflammation Human
- Wound and bone healing Animal
- Blood vessels and organ protection — various injury and toxicity models Animal
- Nervous system — some rodent models of nerve or brain injury Animal
You’ll see much broader lists online. When a claim isn’t tied to a specific study type — and especially when it cites testimonials — treat it as unverified.
What safety topics come up in the literature?
The honest summary is that BPC-157’s safety in humans is largely unknown. Animal studies have generally reported few toxic effects, but animal tolerability doesn’t establish human safety, and there’s no large-scale or long-term human safety data.
Safety topics researchers and regulators raise include:
- Lack of human data — no established side-effect profile, interaction data, or long-term follow-up.
- Theoretical angiogenesis concern — because BPC-157 may promote blood-vessel growth in models, some reviewers have raised a theoretical question about effects in people with existing tumors. This hasn’t been demonstrated; it also hasn’t been ruled out.
- Product quality — unregulated RUO products may be mislabeled, under- or over-dosed, or contaminated, including with bacterial endotoxins.
- Injection-related risks — infection, irritation, and contamination risks apply to any non-sterile or improperly handled injectable, independent of the peptide.
- Special populations — no data on pregnancy, breastfeeding, children, or people with chronic illness.
- Competitive sport — BPC-157 is prohibited by WADA; athletes subject to testing face sanctions.
Online reports of side effects (for example, nausea, dizziness, or injection-site reactions) are anecdotal and can’t be attributed to BPC-157 rather than the product’s contents, handling, or other factors. See peptide side effects.
What is BPC-157’s regulatory status?
In the U.S., BPC-157 is not FDA-approved for any use. Recent history, summarized from FDA notices and published reports (verify against fda.gov before relying on it):
- 2023: FDA placed BPC-157 in Category 2 of bulk drug substances nominated for compounding — substances that “may present significant safety risks.”
- April 2026: BPC-157 was removed from Category 2 after the nominations were withdrawn. FDA has indicated withdrawal reflects no agency determination about safety.
- July 2026: FDA’s Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A bulks list. Advisory votes are not binding; FDA staff had reportedly proposed against listing.
- October 28, 2026: HHS announced an interim enforcement-discretion policy covering licensed-pharmacy (503A) compounding of BPC-157 under conditions. It is not an approval and does not add BPC-157 to the bulks list; Federal Register publication was scheduled for Oct 30, 2026. See the compounding status guide.
Outside the U.S.: status varies by country. In sport: WADA lists BPC-157 under S0 (non-approved substances), prohibited at all times.
Why doesn’t this page include a BPC-157 dosage chart?
Short answer: because there is no established, regulator-approved human dose for BPC-157, and publishing “protocols” would present unproven regimens as if they were advice.
Cluster keywords like bpc-157 dosing chart and bpc-157 tb-500 blend dosage reflect real curiosity — and a common AI failure mode (invented mcg/kg schedules copied from forums). Our gap closure is explicit:
- Animal mg/kg figures do not translate directly to people.
- Small human reports are not a basis for a public dosing table.
- RUO products have unverified content — a “dose” of an unknown vial is not meaningful.
- This site’s calculator and reconstitution pages are unit-math literacy, labeled not medical advice and not prescriptions.
If you need medical guidance, ask a licensed clinician. We will not fill the dosage keyword gap with a fake chart.
Related lab literacy
If you’re reading BPC-157 research or methods sections, these tutorials explain the techniques and vocabulary involved. They’re technique literacy, not instructions for personal use, and none of them provide human dosing.
- TechniqueHow to reconstitute lyophilized peptidesWhat reconstitution means and how concentrations are described
- MaterialsBacteriostatic waterWhat it is and how it differs from sterile water
- HandlingHow peptides are storedTemperature, light, and reconstituted stability
- ToolsPeptide reconstitution calculatorUnit math (mg, mcg, mL) literacy — not a dosing prescription
About doses in studies: animal studies express amounts per kilogram of body weight in rodents. Those figures don’t translate directly to people, and we don’t publish human dosing for unapproved compounds.
Related compounds and comparisons
TB-500 curiosity (answered here, not link-only): TB-500 is a different synthetic peptide, related to thymosin beta-4, that shows up in the same “healing / recovery” search cluster and in “wolverine stack” marketing beside BPC-157. Sharing a forum nickname does not mean they share a mechanism, evidence base, or regulatory path. Both are typically discussed as research peptides with limited human data — details belong on the TB-500 profile and the comparison page.
- ProfileTB-500A synthetic peptide related to thymosin beta-4, often discussed alongside BPC-157
- ComparisonBPC-157 vs TB-500Mechanism, evidence maturity, regulatory status
- GuideWhat are peptides?The fundamentals pillar
- FAQThe “Wolverine stack”Why stack nicknames aren’t evidence
Frequently asked questions
What is BPC-157 used for?
BPC-157 has been studied mainly in animals for tissue repair — including tendon, ligament, muscle, and gut-lining injury models. It isn't approved for any medical use, and human evidence is limited to a few small, uncontrolled reports. Claims about what it "treats" go well beyond what the research currently shows, so treat them as unverified.
Is BPC-157 FDA approved?
No. BPC-157 is not FDA-approved for any condition. In 2026 it was removed from an FDA list of compounding substances with significant safety concerns because its nominations were withdrawn, and an advisory committee recommended it for the compounding bulks list. On Oct 28, 2026 HHS announced interim enforcement discretion for licensed-pharmacy compounding of BPC-157 under conditions. None of these steps is an FDA approval.
Is BPC-157 safe?
Its safety in humans isn't established. Animal studies have reported few toxic effects, but there are no large or long-term human safety studies, no official label, and no known interaction profile. Unregulated research products add risks of mislabeling and contamination. Anyone considering a health decision involving it should discuss it with a licensed clinician.
Does BPC-157 have human studies?
Only a handful, and they're small. Published human data consist mainly of pilot studies and retrospective case series involving few participants, plus limited published results from early clinical development under the code PL 14736. No large randomized controlled trial has been published as of this writing, so effectiveness and safety in people remain open questions.
What does "BPC" stand for?
BPC stands for "body protection compound," the name researchers gave to a protein isolated from human gastric juice. BPC-157 is a 15–amino acid synthetic peptide whose sequence matches a fragment of that protein. The name reflects the original research hypothesis about protecting the gut lining; it isn't evidence that the compound protects the body in people.
What is the "Wolverine peptide" or "Wolverine stack"?
"Wolverine" is an online nickname, usually for BPC-157 combined with TB-500, borrowed from a comic-book character who heals rapidly. It's a marketing term, not a scientific one. No human trials have tested this combination, and the nickname overstates the evidence for either compound on its own.
Is BPC-157 the same as TB-500?
No. They are different molecules that often appear together in search results and "stack" marketing. TB-500 is discussed as related to thymosin beta-4; BPC-157 is a gastric-derived pentadecapeptide sequence. Sharing a nickname does not make them interchangeable. See [BPC-157 vs TB-500](/comparisons/bpc-157-vs-tb500/) and [TB-500](/peptides/tb-500/).
Why is there no BPC-157 dosage / protocol on this page?
Because BPC-157 is not approved for human use, there is no official labeled dose, and animal mg/kg figures do not translate into a responsible public chart. Forum "protocols" and AI-generated mcg schedules are not evidence-based prescribing. We answer the dosage curiosity by refusing to invent one — and by pointing lab readers to unit-math literacy pages that are explicitly not medical advice.
Is BPC-157 banned in sports?
Yes. The World Anti-Doping Agency lists BPC-157 among non-approved substances in section S0 of its Prohibited List, meaning it's banned in and out of competition. Athletes in tested sports can face sanctions for its use, regardless of whether it was labeled "for research use only."
BPC-157 is not approved for human use. This page is educational and does not recommend obtaining or using it. Educational disclaimer.
Sources
- Review — preclinical Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8. PMID: 30915550. Preclinical review.
- Primary — cell/animal Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. PMID: 21030672. Animal and cell study.
- Review — preclinical Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447. PMID: 29998800.
- Development history Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Inflammopharmacology. 2006;14(5-6):214-221. doi:10.1007/s10787-006-1531-7. PMID: 17186181. Describes early clinical-development context; not a large confirmatory efficacy trial and not an FDA approval.
- Anti-doping World Anti-Doping Agency. The 2026 Prohibited List. BPC-157 is named under S0 (Non-Approved Substances). Accessed November 10, 2026.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Nov 10, 2026 · Labels, trial citations, and WADA list wording checked Nov 10, 2026 · How we source & update
Educational disclaimer: Peptide Tutorials publishes educational and research-literacy content only. BPC-157 is not approved for human use. Nothing on this page is medical advice, a dosing recommendation, or encouragement to obtain or use any substance. We don’t sell peptides and don’t link to vendors. Talk to a licensed clinician about any health decision. Read our full disclaimers.